Skip to content
The year in biotech M&A activity got off to a promising start at JPM Week with announcements of some multi-billion-dollar deals. The flurry of […]
Multi-billion-dollar deals at JPM Week augur a busy BIO CEO 2025 Read More »
The increased interest in JPM Week this year is an indication of an improved dealmaking environment for biotech, according to experts for the Biotechnology
Buzz around JPM Week partnering bodes well for biotech dealmaking, BIO says Read More »
The 10-year-old girl was cheerful and upbeat as she spoke to a group of strangers online, but she was also disarmingly clear-eyed about the
Children with rare diseases advocate for legislation in online panel Read More »
This is the fifth in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
Access to health insurance coverage doesn’t always mean patients have access to the health care services and medicines they need. A new poll, commissioned
Access barriers to medicines plague 1 in 3 patients, new poll finds Read More »
“We are seeing an ongoing lack of participation by diverse groups in trials,” said Wayne Frederick, M.D., MBA, President Emeritus of Howard University and
How clinical trial diversity is the path to health equity Read More »
As biotech breakthroughs enable remarkable advances in treatment and prevention of disease, we need similar levels of innovation in access, so patients benefit from
BIO CEO John F. Crowley calls for innovation in access at Milken Health Summit Read More »
Patient advocates from across the country gathered in Washington, D.C., on October 23-24 for the BIO Patient and Health Advocacy Summit (PHAS). This event
PHAS 2024: Patient advocates unite to share stories and address barriers to treatment Read More »
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in
BIO Investor Forum opens with encouraging news on financing Read More »
Sen. Todd Young (R-IN) was recently named Chair of the National Security Commission on Emerging Biotechnology (NSCEB), established by Congress to recommend policy on biotech and national security.
